Euclises Pharmaceuticals
PrivateLast Round
Series A
Extension
Apr 7, 2015
Total Funding Raised
$3.48M
Company Overview
Euclises Pharmaceuticals is a biotechnology company that develops novel COX-2 inhibitors for the treatment of oncology patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Euclises Pharmaceuticals Comparables
Compare Euclises Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Owkin | 73% | |
| Yiviva | 71% | |
| Kainova Therapeutics | 70% |
Euclises Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Apr 7, 2015 | ||||
| Series A | Sep 9, 2014 | ||||
| Seed | Jun 11, 2012 |
Euclises Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cultivation Capital | Series A Extension, Series A |
| Missouri Technology Corporation | Series A |
| St. Louis Arch Angels | Series A Extension, Seed, Series A |
| BioGenerator Ventures | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 24, 2024
Monthly visitors increased 60% MoM.
- Apr 7, 2015
$2M round with BioGenerator Ventures and Cultivation Capital.
Euclises Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Euclises Pharmaceuticals's valuation, stock price, and market status.
Is Euclises Pharmaceuticals a public or private company?
Euclises Pharmaceuticals is a private company.
What is the current stock price of Euclises Pharmaceuticals?
Euclises Pharmaceuticals is a private company with no public stock price. Caplight tracks Euclises Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is Euclises Pharmaceuticals worth (valuation)?
Valuation information for Euclises Pharmaceuticals is not publicly available.
Can I buy Euclises Pharmaceuticals stock?
Euclises Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Euclises Pharmaceuticals's last funding round?
Euclises Pharmaceuticals's most recent funding round was Series A Extension on April 7, 2015.
Who are the main investors in Euclises Pharmaceuticals?
Key investors in Euclises Pharmaceuticals include Cultivation Capital.
Will Euclises Pharmaceuticals IPO soon?
No public IPO plans have been announced for Euclises Pharmaceuticals.
How can I track Euclises Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Euclises Pharmaceuticals's secondary market activity and sign up for updates.